Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Global health

Counterfeit medicines are a growing threat to global health, WHO meeting hears

Substandard and counterfeit medicines pose a growing threat to global health and greater global efforts are needed to counter the problem, experts have warned at an international forum.  

Speaking at a session on 27 May 2016 at the annual assembly of the World Health Organization, Zuzana Kusynova, policy adviser at the International Pharmaceutical Federation (FIP), which represents pharmacists and pharmaceutical scientists, said it was important to safeguard the legitimate supply chain of medicines. 

“It was vital for pharmacists to refer cases to authorities if they find suspected cases of substandard, spurious, or counterfeit medicines,” she added. 

These products are known as SSFFC — substandard, spurious, falsely labelled, falsified and counterfeit medicines — and can affect both branded and generic products.

Hans Hogerzeil, professor of global health at the University of Groningen in the Netherlands, pointed out that there are no good estimates on the frequency of falsified medicines, but that “we have some information on the frequency of substandard medicines”. 

The WHO says there are many estimates of the scope and scale of the market in SSFFC medical products but little validated evidence to underpin those estimates. 

Since 2013, when the WHO asked member states to report SSFFC incidents in a systematic format, more than 1,114 medical products have been reported covering main therapeutic categories. If any of the notifications pose a serious threat to global health, the WHO issues a global medical product alert.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201237

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • World Health Organization offices, Geneva

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.